Prelude therapeutics' smarca2 degrader prt3789 demonstrated promising initial clinical activity and safety profile in phase 1 trial

-  encouraging signs of anti-tumor activity including objective responses observed in patients with smarca4-mutated non-small cell lung cancer (nsclc) and esophageal cancer in early prt3789 monotherapy dose escalation
PRLD Ratings Summary
PRLD Quant Ranking